Barings Corporate Investors
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MCI research report →
Price Chart
About the company
The Babson Capital Corporate Investors trust, which was previously identified simply as Babson Capital Corporate Investors, operates as a closed-end mutual fund focused on fixed-income investments. This entity, launched and managed by Barings LLC, primarily allocates capital within the United States' fixed-income markets. Its investment strategy targets securities from companies spanning various diversified sectors.
- CEO
- Clifford Michael Noreen
- IPO
- 1980
- HQ
- Charlotte, NC, US
Get TickerSpark's AI analysis on MCI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $376.17M
- P/E
- 13.26
- PEG
- -0.61
- P/S
- 10.35
- P/B
- 1.10
- EV/EBITDA
- 0.00
- Div Yield
- 8.74%
- Gross Margin
- 100.00%
- Op Margin
- 84.18%
- Net Margin
- 77.18%
- ROE
- 8.12%
- ROIC
- 7.24%
Latest fiscal year · YoY change
- Revenue
- $32.74M-24.4%
- Gross Profit
- $30.18M-20.4%
- Op Income
- $28.77M
- Net Income
- $28.06M-21.1%
- EPS
- $1.37-21.7%
- OCF Growth
- -34.0%
- FCF Growth
- -34.0%
- 52W High
- $23.00
- 52W Low
- $16.21
- 50D MA
- $17.13
- 200D MA
- $18.75
- Beta
- 0.32
- RSI (14)
- 73
- Avg Volume
- 33.65K
No earnings-call transcripts are available for MCI yet.
- Free Float
- 0.0%
- Shares Outstanding
- 20.56M
- Float Shares
- 0
of shares held by institutions
61 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bhk Investment Advisors, LLC | 386.99K | ▲ 9.46K |
| Global Wealth Strategies & Associates | 299.75K | ▲ 12.93K |
| Curbstone Financial Management Corp | 287.73K | ▼ 1.40K |
| Barings LLC | 219.66K | 0 |
| Cetera Investment Advisers | 211.97K | ▲ 31.58K |
| Secure Asset Management, LLC | 208.97K | ▲ 8.12K |
| Morgan Stanley | 176.85K | ▼ 687 |
| Sky Investment Group LLC | 175.14K | ▲ 4.85K |
| Smith Asset Management Co., LLC | 169.55K | ▼ 3.37K |
| Cambridge Investment Research Advisors, Inc. | 128.06K | ▲ 10.54K |
| Beacon Pointe Advisors, LLC | 94.00K | ▲ 28.35K |
| Tsp Capital Management Group, LLC | 86.73K | ▲ 4.45K |
Held by 1 ETFs
Biggest fund positions in MCI by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 6, 26 | Emery Christina | other | 45.023 |
| Jul 9, 26 | Emery Christina | other | 43.311 |
| Jun 25, 26 | Emery Christina | other | 43.038 |
| Jun 17, 26 | NOREEN CLIFFORD M | sell | 9,877 |
| Jun 11, 26 | Emery Christina | other | 43.112 |
| May 29, 26 | NOREEN CLIFFORD M | other | 6,856.05 |
| May 28, 26 | Emery Christina | other | 41.654 |
| May 14, 26 | Emery Christina | other | 43.386 |
| Apr 30, 26 | Emery Christina | other | 42.599 |
| Apr 16, 26 | Emery Christina | other | 41.816 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MCI coverage
Recent articles, reports, and earnings notes.
No research on MCI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MCI report →Barings Corporate Investors: Best In Class, Now Priced To Buy Again
seekingalpha.com · Aug 17
Barings Corporate Investors Reports Preliminary Second Quarter 2026 Results and Announces Quarterly Cash Dividend Of $0.40 Per Share
businesswire.com · Aug 13
PL Gold Mine Restart Update High Grade Gold Results, Resource Expansion Potential and Operational Readiness Update
newsfilecorp.com · Jul 29
Why This 15.3%-Paying CEF Is Making Big Changes
forbes.com · Jul 28
More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
gurufocus.com · Jul 14
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treat
gurufocus.com · Jul 14
MCI: Easing Share Price Leads To Premium Decline; This Could Be The Reason
seekingalpha.com · Jun 29
Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
gurufocus.com · Jun 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.